The Phase 1/2 Open-Label, Single Arm, Multi-Center Clinical Trial is Testing Kamada’s Hyper-immune IgG Product in Hospitalized, Non-Ventilated COVID-19 Patients with Pneumonia Symptoms Improvement Observed in 11 of the 12…
The Study of KEDRAB® (Rabies Immune Globulin [Human]) Conducted in Children was the First and Only Pediatric Study for any HRIG Available in U.S. The Study Met its Primary Objective,…
Click here for the recording of Kamada second quarter 2020 investor call. Second Quarter Revenues were $1 million, Compared to $35.3 million in 2019, First Half 2020 Revenues were $66.4 million,…
Study Participants are Hospitalized, Non-ventilated COVID-19 Patients with Pneumonia Encouraging Neutralization Activity Observed with Virus Neutralization Assay Pre-IND Meeting with U.S. FDA to be Conducted in Current Quarter, with U.S….
Kamada Completed Manufacturing and Released the First Batch of its Plasma-Derived Immunoglobulin Product for Coronavirus Disease (COVID-19) and it is Available for Compassionate Use Treatment in Israel; Additional Production is…
Total Revenues were $33.3 Million, an Increase of 24% Year-over-Year Net Income was $5.2 Million, an Increase of 6% Year-over-Year Company Reports Continued Progress of its Development Program of a…
Rehovot, Israel, May 11, 2020 — Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the first quarter ended March 31,…
Kamada is Responsible for Product Development, Manufacturing, Clinical Development, and Regulatory Submissions, as well as Distribution in Territories not under Kedrion’s Responsibility Kedrion is Responsible for the Collection and Supply…
Rehovot, Israel, March 11, 2020 – Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial-stage plasma-derived biopharmaceutical company, today provided an update on progress related to its proprietary hyper-immunoglobulin (IgGs) product…
Total Revenues for Fiscal 2019 were $127.2 million, up 11% as Compared to 2018 Gross Profit for Fiscal 2019 was $49.7 Million, up 20% as Compared to 2018 Adjusted EBITDA…